Thomas Lindner

7.6k total citations · 5 hit papers
57 papers, 5.6k citations indexed

About

Thomas Lindner is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Thomas Lindner has authored 57 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Cancer Research and 15 papers in Surgery. Recurrent topics in Thomas Lindner's work include Peptidase Inhibition and Analysis (28 papers), Protease and Inhibitor Mechanisms (19 papers) and Cardiac Structural Anomalies and Repair (14 papers). Thomas Lindner is often cited by papers focused on Peptidase Inhibition and Analysis (28 papers), Protease and Inhibitor Mechanisms (19 papers) and Cardiac Structural Anomalies and Repair (14 papers). Thomas Lindner collaborates with scholars based in Germany, United States and France. Thomas Lindner's co-authors include Uwe Haberkorn, Clemens Kratochwil, Frederik L. Giesel, Walter Mier, Jürgen Debus, Annette Altmann, Anastasia Loktev, Dirk Jäger, Paul Flechsig and Frederik Marmé and has published in prestigious journals such as Angewandte Chemie International Edition, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Thomas Lindner

56 papers receiving 5.6k citations

Hit Papers

68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of ... 2018 2026 2020 2023 2019 2018 2018 2018 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
    2019 964 citations Clemens Kratochwil, Paul Flechsig et al. Journal of Nuclear Medicine profile →
  2. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
    2018 644 citations Thomas Lindner, Anastasia Loktev et al. Journal of Nuclear Medicine profile →
  3. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
    2018 534 citations Anastasia Loktev, Thomas Lindner et al. Journal of Nuclear Medicine profile →
  4. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
    2018 488 citations Frederik L. Giesel, Clemens Kratochwil et al. Journal of Nuclear Medicine profile →
  5. Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
    2019 370 citations Anastasia Loktev, Thomas Lindner et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Lindner Germany 31 4.4k 2.2k 2.2k 1.4k 907 57 5.6k
Christoph Wagener Germany 47 2.5k 0.6× 757 0.3× 586 0.3× 2.0k 1.4× 3.1k 3.4× 154 6.5k
Neil Senzer United States 43 3.9k 0.9× 1.0k 0.5× 468 0.2× 267 0.2× 3.6k 4.0× 176 7.8k
Gal Markel Israel 41 2.5k 0.6× 343 0.2× 380 0.2× 503 0.4× 1.5k 1.7× 126 5.8k
Björn Öbrink Sweden 42 1.0k 0.2× 313 0.1× 566 0.3× 1.2k 0.8× 2.4k 2.7× 99 5.0k
Olivier Gires Germany 42 3.4k 0.8× 1.3k 0.6× 427 0.2× 462 0.3× 2.8k 3.1× 109 6.2k
Kunyu Yang China 36 1.7k 0.4× 831 0.4× 528 0.2× 527 0.4× 1.5k 1.6× 173 4.6k
Suneale Banerji United Kingdom 29 2.2k 0.5× 226 0.1× 798 0.4× 152 0.1× 2.0k 2.2× 37 5.0k
Benjamin Swanson United States 24 1.6k 0.4× 433 0.2× 691 0.3× 291 0.2× 2.0k 2.2× 62 3.8k
B M Fendly United States 39 3.9k 0.9× 588 0.3× 182 0.1× 3.0k 2.1× 3.5k 3.8× 59 7.6k
Mitchell Ho United States 47 2.1k 0.5× 457 0.2× 344 0.2× 1.4k 1.0× 2.6k 2.9× 142 6.5k

Countries citing papers authored by Thomas Lindner

Since Specialization
Citations

This map shows the geographic impact of Thomas Lindner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Lindner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Lindner more than expected).

Fields of papers citing papers by Thomas Lindner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Lindner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Lindner. The network helps show where Thomas Lindner may publish in the future.

Co-authorship network of co-authors of Thomas Lindner

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Lindner. A scholar is included among the top collaborators of Thomas Lindner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Lindner. Thomas Lindner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Helisch, Andreas, Clemens Kratochwil, Christian Kleist, et al.. (2024). Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors. Journal of Nuclear Medicine. 65(12). jnumed.124.268386–jnumed.124.268386. 1 indexed citations
2.
Kaiser, Christian, Jörn Gethmann, Jeannette Kliemt, et al.. (2023). Efficacy of Oral Rabies Vaccine Baits Containing SPBN GASGAS in Domestic Dogs According to International Standards. Vaccines. 11(2). 307–307. 12 indexed citations
3.
Rathke, Hendrik, Stefan Fuxius, Frederik L. Giesel, et al.. (2021). Two Tumors, One Target. Clinical Nuclear Medicine. 46(10). 842–844. 30 indexed citations
4.
Koerber, Stefan A., Katharina Dendl, Matthias Uhl, et al.. (2021). Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 48(12). 3918–3924. 39 indexed citations
5.
Dendl, Katharina, Frederik L. Giesel, Clemens Kratochwil, et al.. (2021). FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies. European Journal of Nuclear Medicine and Molecular Imaging. 49(2). 721–731. 48 indexed citations
6.
Giesel, Frederik L., Clemens Kratochwil, Katharina Dendl, et al.. (2021). Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 48(13). 4377–4385. 148 indexed citations
7.
Naka, Sadahiro, Tadashi Watabe, Thomas Lindner, et al.. (2021). One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment. EJNMMI Radiopharmacy and Chemistry. 6(1). 28–28. 16 indexed citations
8.
Watabe, Tadashi, Yuwei Liu, Kazuko Kaneda‐Nakashima, et al.. (2019). Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. Journal of Nuclear Medicine. 61(4). 563–569. 228 indexed citations
9.
Lindner, Thomas, Anastasia Loktev, Frederik L. Giesel, et al.. (2019). Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharmacy and Chemistry. 4(1). 16–16. 153 indexed citations
10.
Yang, Jianquan, Jingli Xu, René González, et al.. (2018). 68 Ga-DOTA-GGNle-CycMSH hex targets the melanocortin-1 receptor for melanoma imaging. Science Translational Medicine. 10(466). 39 indexed citations
11.
Roesch, Saskia, Thomas Lindner, Max Sauter, et al.. (2018). Comparison of the RGD Motif–Containing αvβ6Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. Journal of Nuclear Medicine. 59(11). 1679–1685. 42 indexed citations
12.
Domhan, Cornelius, Philipp Uhl, Stefan Zimmermann, et al.. (2018). A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. International Journal of Antimicrobial Agents. 52(1). 52–62. 30 indexed citations
13.
Brings, Sebastian, Thomas Fleming, Barbro Beijer, et al.. (2016). A scavenger peptide prevents methylglyoxal induced pain in mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1863(3). 654–662. 32 indexed citations
14.
Zoller, Frederic, Annette Markert, Philippe Barthe, et al.. (2013). A Disulfide‐Constrained Miniprotein with Striking Tumor‐Binding Specificity Developed by Ribosome Display. Angewandte Chemie International Edition. 52(45). 11760–11764. 11 indexed citations
15.
Rösler, U., Uwe Truyen, Jörg Lehmann, et al.. (2010). Persistenz, Ausscheidung und Wirksamkeit der attenuierten Salmonella Typhimurium Vakzine Salmoporc® bei Saugferkeln. Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft). 91. 2 indexed citations
16.
Rösler, U., et al.. (2010). Persistence, excretion and efficacy of an attenuated Salmonella vaccine in suckling piglets.. Fraunhofer-Publica (Fraunhofer-Gesellschaft). 91(1). 59–65. 8 indexed citations
17.
Lindner, Thomas, et al.. (2008). Antikörperantwort nach Impfung von Mastschweinen mit einem Salmonella-Typhimurium-Lebendimpfstoff in Abhängigkeit von der Applikationsform. Berliner und Münchener tierärztliche Wochenschrift. 121. 2 indexed citations
18.
Zimmermann, Klaus F., et al.. (2004). Native Versus Recombinant High-Mobility Group B1 Proteins: Functional Activity In Vitro. Inflammation. 28(4). 221–229. 51 indexed citations
19.
Lindner, Thomas, et al.. (2003). Immunprophylaxe von Salmonella-Infektionen beim Schwein. 84. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christoph Wagener Breakdown of academic impact, for papers by Neil Senzer Breakdown of academic impact, for papers by Gal Markel Breakdown of academic impact, for papers by Björn Öbrink Breakdown of academic impact, for papers by Olivier Gires Breakdown of academic impact, for papers by Kunyu Yang Breakdown of academic impact, for papers by Suneale Banerji Breakdown of academic impact, for papers by Benjamin Swanson Breakdown of academic impact, for papers by B M Fendly Breakdown of academic impact, for papers by Mitchell Ho
Rankless by CCL
2026